Kyverna Therapeutics (“Kyverna”), a cell therapy company with the mission of engineering a new class of therapies for serious autoimmune diseases, today announced the approval of its first Clinical Trial Application (CTA) by the Paul-Ehrlich-Institut (PEI) in Germany for KYV101, a novel therapy for the treatment of lupus nephritis (LN).
